Introduction {#s1}
============

According to the World Health Organization (WHO), tuberculosis (TB) ranks as the second leading cause of death from an infectious disease worldwide, after HIV (WHO\|Global tuberculosis report 2014, [@B75]). It is estimated that one third of the world\'s population is infected with *Mycobacterium tuberculosis*, the causative agent of TB and 8.6 million new TB cases were reported in 2012 alone (WHO\|Global tuberculosis report 2013, [@B74]). In order to control this epidemic there is a critical need for the development of effective and affordable anti-TB therapy and diagnostic tools.

Harnessing the power of the field of proteomics provides a unique opportunity to identify novel protein candidates for diagnosis and drug targets of pathogenic bacteria. Of particular interest is the identification of proteins with post-translational modifications (PTMs) as these modifications are often critical to protein functions, such as regulating protein-protein interactions, subcellular localization or modification of catalytic sites (Seo and Lee, [@B61]; Gupta et al., [@B24]). Protein phosphorylation is an important reversible PTM that directly or indirectly regulates signal transduction cascades linking the intracellular and extracellular environments. In bacteria, protein phosphorylation plays a fundamental role in the regulation of key processes ranging from metabolism and cellular homeostasis to cellular signaling which can be mediated by two classes of phosphorylation events (Cozzone, [@B13]). The underlying molecular mechanisms regulating protein phosphorylation and dephosphorylation is of great physiological importance due to its ability to ultimately affect protein activity, function, half-life or subcellular localization (McConnell and Wadzinski, [@B42]). Until recently it was thought that histidine/aspartate phosphorylation was the main mediator of signal transduction in bacteria (Frasch and Dworkin, [@B18]). However, with the advancement of mass spectrometry-based analyses serine/threonine and tyrosine kinases have been identified in a number of different bacteria (Macek et al., [@B40]; Macek and Mijakovic, [@B39]; Mijakovic and Macek, [@B44]).

The *M. tuberculosis* genome encodes 11 Serine/Threonine kinases (STPK\'s) (PknA, PknB, PknD, PknE, PknF, PknG, PknH, PknI, PknJ, PknK, PknL), two tyrosine phosphatases (PtpA, PtpB) and 11 two-component systems, highlighting the complexity of signaling network mediated by protein phosphorylation and thereby their potential as drug targets (Chopra et al., [@B10]; Koul et al., [@B29]; Sharma et al., [@B62]; Sala and Hartkoorn, [@B59]). Prisic et al. described the Serine/Threonine (S/T) phosphorylation profiles of the laboratory strain *M. tuberculosis* H~37~Rv under 6 different culture conditions (Prisic et al., [@B54]). This study identified 301 phosphorylated proteins after combining data from six different culture conditions (Prisic et al., [@B54]) and identified four phosphorylated STPKs, ribosomal and ribosome-associated proteins as well as phosphorylated substrates which suggest that protein phosphorylation provides a mechanism for regulating key physiological process during infection. A more recent study of H~37~Rv further expanded the knowledge of the phosphoproteome by identifying novel tyrosine (Y) phosphorylated proteins in *M. tuberculosis* further supporting the broad regulation of its physiology by phosphorylation (Kusebauch et al., [@B33]).

In this study we report the phosphoproteome of a previously described clinical Beijing genotype *M. tuberculosis* isolate at early-logarithmic growth phase in liquid culture to provide further insight the influence of S/T/Y phosphorylation events on bacterial growth and virulence (de Souza et al., [@B15]). We used a combination of strong cation exchange (SCX) with Titanium dioxide (TiO~2~) enrichment in a mass spectrometry-based phosphoproteomic analysis of a hyper-virulent clinical *M. tuberculosis* isolate (de Souza et al., [@B15]). We confirmed the presence of previously described *M. tuberculosis* phosphorylated proteins and also identified novel phosphorylated proteins and sites. In addition, this dataset identified novel tyrosine phosphorylation events, and thereby confirmed that there are multiple tyrosine kinase targets in this clinically relevant *M. tuberculosis* strain.

Materials and methods {#s2}
=====================

Cell culture and lysate preparation
-----------------------------------

A previously described hyper-virulent clinical Beijing genotype *Mycobacterium tuberculosis* isolate, SAW5527, isolated from a TB patient attending a primary health care clinic in the Western Cape province, South Africa was used for this phosphoproteomics analysis (de Souza et al., [@B15]). Secondary cultures were inoculated into 50 ml 7H9 Middlebrooks medium supplemented with Dextrose and Catalase and incubated at 37°C until early-logarithmic phase (OD~600~ between 0.6 and 0.7). Mycobacterial cells were collected by centrifugation (2000 × g for 10 min at 4°C) and washed two times with cold lysis buffer containing 10 mM Tris-HCl (pH 7.4), 0.1% Tween-80, Complete Protease inhibitor cocktail (Roche, Mannheim Germany) and Phosphatase inhibitor cocktail (Roche, Mannheim Germany). An equal amount of 0.1 mm glass beads (Biospec Products Inc., Bartlesville, OK) was added to the cell pellet after centrifugation together with cold 300 μl lysis buffer and 10 μl DNaseI (2U/ml) (NEB, New England Laboratories). Lysis was achieved by mechanical bead-beating in a Rybolyser (Bio101 SAVANT, Vista, CA) for 6 cycles of 20 s at a speed of 4.0 m.s^−1^, with 1 min cooling periods on ice. The whole cell lysates were filter-sterilized with a sterile 0.22 μm pore acrodisc 25 mm PF syringe filter (Pall Life Sciences, Pall Corporation, Ann Arbour, MI) and stored at −80°C. The protein concentration of the whole cell lysate was determined using the RC DC Protein assay according to manufacturer\'s instructions (BioRad). A single biological replicate was analyzed in triplicate for downstream phosphoproteomic analysis.

Filter aided sample preparation and trypsin digestion
-----------------------------------------------------

Four milligrams of concentrated whole cell lysate proteins was heated in 4% SDS buffer and 0.1 M dithiothreitol (DTT) in 100 mM Tris/HCl pH 7.5. The samples were processed using Filter Aided Sample Preparation (FASP) (Wiśniewski et al., [@B76]). In brief, 4 mg dried whole cell lysate protein was resuspended in 250 μl of urea (UA) and loaded onto a 15 ml Amicon filtration device (30 kDa MWCO) and centrifuged at 2000 × g for 40 min at 25°C. After centrifugation, the flow-through was collected in a clean falcon tube and discarded. The concentrated whole cell lysate proteins in the filter unit were diluted in 2 ml 8 M Urea in 0.1 M Tris/HCl (pH 8.5) and re-centrifuged to remove the SDS. The flow-through was discarded and the remaining proteins in the filter unit were alkylated by mixing with 1.5 ml 50 mM iodacetamide (IAA) and incubated in the dark for 20 min to irreversibly modify cysteine. The alkylated proteins were equilibrated with 2 ml 50 mM ammonium bicarbonate (ABC) and digested with trypsin (Promega) in a protein to enzyme ratio of 100:1 at 37°C overnight. After trypsin digestion the filter unit is transferred to a clean collection tube and the peptides were eluted by centrifuged at 14 000 × g for 10 min. The eluted peptides were diluted in 50 μl water to avoid desalting for further processing of the peptide and acidified with trifluoroacetic acid (TFA).

Fractionation of peptides by strong cation exchange (SCX)
---------------------------------------------------------

Extracted trypsin digested peptides were diluted to a volume of 7 ml in Solvent A (5 mM monopotassium phosphate (KH~2~PO~4~) 30% acetonitrile (ACN), pH 2.7). The pH of the diluted peptide samples was adjusted to 2.7 and made up to a volume of 10 ml with 100% ACN. The respective peptide samples were then separated at pH 2.7 by strong cation exchange (SCX ) by loading each peptide mixture onto a cation exchanger column (3.0 mm × 20 cm) (Poly LC, Columbia, MD) containing 5 μm polysulfoethyl aspartamine beads with a 200 Å pore size and a flow rate of 350 μl/min^−1^ equilibrated with SCX solvent A. The flow-through was collected and the bound peptides were eluted from the columns using an increasing salt gradient (0--30%) containing 5 mM KH~2~PO~4~ pH and 150 mM KCl. A total of 9 fractions were collected; 5 fractions generated by SCX based on UV absorbance (220 and 280), 3 from the flow-through and 1 salvage fraction (containing washes from the cation exchanger column) from the SCX column as an additional fraction.

Enrichment of phosphopeptides with TiO~2~ beads
-----------------------------------------------

All nine fractions (5 SCX, 3 SCX flow-through, 1 salvage fraction) were subjected to Titanium dioxide (TiO~2~) phosphopeptide enrichment. The TiO~2~-beads,10 μm in size, (GL Sciences, Inc., Japan) was resuspended 30 mg/ml dihydrobenzoic acid (DHB) (Sigma) to prevent non-specific binding. Each of the 9 fractions was incubated 4 times with TiO~2~ at a peptide to bead ratio of 1:2--1:8. Each fraction was rotated for 30 min, and then briefly centrifuged (14,000 g × 30 s). The supernatants were aspirated and transferred to a new labeled tube and the phosphopeptides bound to the TiO~2~beads were washed twice with 30% ACN and 3% TFA followed by washing twice with 75% ACN and 0.3% TFA. The enriched phosphorylated peptides were eluted with elution buffer containing 25% ammonia and ACN pH10. The eluted phosphopeptides were desalted using in house prepared C~18~ Stage tips.

LC-MS/MS analysis
-----------------

The peptides were separated on a column packed in-house with C18 beads (reprosil-AQ Pur, Rd Maisch) on an Proxeon Easy-nLC system (Proxeon Biosystems, Odense, Denmark) using a binary gradient with buffer A (0.5% acetic acid in water) and buffer B (0.5% acetic acid and 80% ACN). The 4 μl of the enriched phosphopeptides from each of the 9 fractions were injected 3 times and were loaded directly without any trapping column with buffer A at a flow rate of 500 nl/min. Elution was carried out at a flow rate of 250 nl/min, with a linear gradient from 10 to 35% buffer B over a period of 95 min followed by 50% buffer B for 15 min. At the end of the gradient the column was washed with 90% buffer B and equilibrated with 5% buffer B for 10 min. The LC system was directly coupled in-line with the LTQ-Orbitrap Velos instrument (Thermo Fisher Scientific) via the Proxeon Biosystems nanoelectrospray source. The mass spectrometer was programmed to acquire in a data-dependant mode with a resolution of 30,000 at 400 m/z with lock mass option enabled for the 445.120025. However, the target lock mass abundance was set to 0% in order to save the injection time for lock mass. For full scans 1E6 ions were accumulated within a maximum injection time of 250 ms in the C trap and detected in the Orbitrap mass analyser. The 10 most intense ions with charge states ≥2 were sequentially isolated and fragmented by high-energy collision dissociation (HCD) mode in the collision cell with normalized collision energy of 40% and detected in the Orbitrap analyser at 75,000 resolution. For HCD based method, the activation time option in the Xcalibur file was set to 0.1 ms. For the high-low strategy, full scans were acquired in the Orbitrap analyser at 60,000 resolution as parallel acquisition is enabled in the high-low mode. Up to the 10 most intense peaks with charge states ≥2 were selected for sequencing to a target value of 5000 with a maximum injection time of 25 ms and fragmented in the ion trap by HCD with normalized collision energy of 35%, activation of 0.25 and activation time of 10 ms.

Database search
---------------

The raw data acquired were processed using MaxQuant software version (1.4.1.2) and processed as per default workflow. Since HCD spectra were acquired in profile mode, deisotoping was performed similar to survey MS scans to obtain singly charged peak lists and searched against the *M. tuberculosis* H~37~Rv protein database (version R11 tuberculist.epfl.ch). The search included cysteine carbamidomethylation as a fixed modification while N-acetylation, oxidation of methionine and phosphorylation at serine, threonine and tyrosine were set as variable modifications. Up to two missed cleavages were allowed for protease digestion and a peptide had to be fully tryptic. Identifications were filtered at 1% FDR at three levels namely; site, peptide and protein using reversed sequences. As such there is no fixed cut-off score threshold but instead spectra were accepted until the 1% false discovery rate (FDR) is reached. Only peptides with a minimum length of 7 amino acids were considered for identification and detected in at least one or more of the replicates. All phosphopeptide spectra were manually validated by applying stringent acceptance criteria: only phosphorylation events on S/T/Y with a localization probability of ≥0.75 and PEP ≤ 0.01 were used for further analysis and reported as high confidence localized phosphosites.

Gene ontology analysis
----------------------

The categorization of identified phosphorylated proteins in terms of functional categorization, molecular function, biological processes and cellular components was carried out using TubercuList-*Mycobacterium tuberculosis* Database.

Results {#s3}
=======

In this study we set out to analyse the phosphoproteome of a hyper-virulent Beijing genotype *M. tuberculosis* isolate by extracting whole cell lysate proteins at early-logarithmic growth (OD~600~ of 0.8) (Figure [1](#F1){ref-type="fig"}) which resulted in the identification of 619 MS/MS spectra. The 274 LC-MS/MS spectra that fulfilled the criteria for high confidence phosphosites identified a total of 414 (38:59:3%) S/T/Y phosphorylation sites present in 214 *M. tuberculosis* H~37~Rv proteins (Supplementary Table [S2](#SM1){ref-type="supplementary-material"}; Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}).

![**Growth curves of hyper-virulent *M. tuberculosis* Beijing strain**. Growth monitored over a 24 day period using OD~600~ measurements in 7H9 Middlebrooks liquid media supplemented with dextrose and catalase.](fmicb-06-00006-g0001){#F1}

Of the 401 serine/threonine phosphorylation sites (pS/T), only 156 had been previously described for *M. tuberculosis* (Table [1](#T1){ref-type="table"}). Only 6 of 13 tyrosine phosphorylation sites (pY) has been previously described for *M. tuberculosis* (Kusebauch et al., [@B33]). The remaining 245 pS/T and 7 pY were uniquely identified in this study (Supplemental Table [S2](#SM1){ref-type="supplementary-material"}). To determine whether phosphorylated proteins were differentially represented in any particular cellular process, we grouped the phosphorylated proteins based on their functional category according to Tuberculist (Lew et al., [@B35]) (Figure [2](#F2){ref-type="fig"}). One hundred and seventy (79.4%) of the phosphorylated proteins had an annotated function, while the remaining 59 phosphorylated proteins (20.5%) were assigned as hypothetical. The biological function of the annotated proteins varied from transcription, translation, protein biosynthesis, fatty acid metabolism to phosphorylation. Our analysis identified phosphorylated forms of the 9 of the 11 *M. tuberculosis* STPK\'s: PknA, PknB, PknD, PknF, PknG PknE, PknH, PknJ, and PknL (Table [2](#T2){ref-type="table"}). Of these, phosphorylated forms of PknE, PknH, PknJ, and PknL had not been previously described in *M. tuberculosis*.

###### 

**List of phosphopeptides identified in this and previous studies of *M. tuberculosis***.

  **Rv numbers**   **Protein name**   **Phosphopeptides**                                                                                                       **Phospho-residue**   **References**
  ---------------- ------------------ ------------------------------------------------------------------------------------------------------------------------- --------------------- --------------------------------------
  Rv0007           Rv0007             FISGASAPVTGPAAAVR                                                                                                         Not known             Prisic et al., [@B54]
                                      FIS[^\*^](#TN1s){ref-type="table-fn"}GAS[^\*^](#TN1s){ref-type="table-fn"}APVT[^\*^](#TN1s){ref-type="table-fn"}GPAAAVR   S; T                  This study
                                      FIS[^\*^](#TN1s){ref-type="table-fn"}GASAPVT[^\*^](#TN1s){ref-type="table-fn"}GPAAAVR                                     S; T                  This study
  Rv0014c          PknB               AIADSGNSVTQTAAVIGTAQYLSPEQAR                                                                                              Not known             Prisic et al., [@B54]
                                      AIADSGNSVT[^\*^](#TN1s){ref-type="table-fn"}QT[^\*^](#TN1s){ref-type="table-fn"}AAVIGTAQYLSPEQAR                          T                     This study
                                      AIADSGNS[^\*^](#TN1s){ref-type="table-fn"}VT[^\*^](#TN1s){ref-type="table-fn"}QTAAVIGTAQYLSPEQAR                          S; T                  This study
                                      TSLLSSAAGNLSGPRTDPLPR                                                                                                     Not known             Prisic et al., [@B54]
                                      TSLLSSAAGNLS[^\*^](#TN1s){ref-type="table-fn"}GPRTDPLPR                                                                   S                     This study
                                      TSLLSSAAGNLSGPRT[^\*^](#TN1s){ref-type="table-fn"}DPLPR                                                                   T                     This study
  Rv0015c          PknA               RPFAGDGALT[^\$^](#TN1sss){ref-type="table-fn"}VAMK                                                                        T                     Prisic et al., [@B54]; This study
  Rv0020c          FhaA               FEQSSNLHTGQFR                                                                                                             Not known             Prisic et al., [@B54]
                                      FEQS[^\*^](#TN1s){ref-type="table-fn"}SNLHT[^\*^](#TN1s){ref-type="table-fn"}GQFR                                         S; T                  This study
                                      HPDQGDY[^\$^](#TN1sss){ref-type="table-fn"}PEQIGYPDQGGYPEQR                                                               Y                     Kusebauch et al., [@B33]; This study
                                      QDYGGGADY[^\$^](#TN1sss){ref-type="table-fn"}TR                                                                           Y                     Kusebauch et al., [@B33]; This study
                                      VPGY[^\$^](#TN1sss){ref-type="table-fn"}APQGGGYAEPAGR                                                                     Y                     Kusebauch et al., [@B33]; This study
  Rv0175           Rv0175             AADSAESDAGADQTGPQVK                                                                                                       Not known             Prisic et al., [@B54]
                                      AADSAESDAGADQT[^\*^](#TN1s){ref-type="table-fn"}GPQVK                                                                     T                     This study
  Rv0204c          Rv0204c            DPPT[^\$^](#TN1sss){ref-type="table-fn"}DPNLR                                                                                                   Prisic et al., [@B54]; This study
  Rv0227c          Rv0227c            GGFEEPVPGAEAETEKLPTQRPDFPR                                                                                                Not known             Prisic et al., [@B54]
                                      GGFEEPVPGAEAET[^\$^](#TN1sss){ref-type="table-fn"}EK                                                                      T                     Prisic et al., [@B54]; This study
  Rv0351           GrpE               RIDPET[^\#^](#TN1ss){ref-type="table-fn"}GEVR                                                                             T                     Prisic et al., [@B54]
                                      IDPET[^\*^](#TN1s){ref-type="table-fn"}GEVR                                                                               T                     This study
  Rv0389           PurT               AAGHQVQPQT[^\$^](#TN1sss){ref-type="table-fn"}GGVSPR                                                                      T                     Prisic et al., [@B54]; This study
  Rv0410c          PknG               SGPGTQPADAQTAT[^\#^](#TN1ss){ref-type="table-fn"}SATVRPL                                                                  T                     O\'Hare et al., [@B50]
                                      S[^\*^](#TN1s){ref-type="table-fn"}GPGT[^\*^](#TN1s){ref-type="table-fn"}QPADAQTATSATVR                                   S; T                  This study
                                      SGPGTQPADAQTAT[^\*^](#TN1s){ref-type="table-fn"}S[^\*^](#TN1s){ref-type="table-fn"}ATVRPLSTQAVFR                          S; T                  This study
                                      SGPGTQPADAQTAT[^\*^](#TN1s){ref-type="table-fn"}SAT[^\*^](#TN1s){ref-type="table-fn"}VR                                   T                     This study
                                      PLST[^\#^](#TN1ss){ref-type="table-fn"}QAVFRPDFGDEDNFPHPTLGPDTEPQDR                                                       T                     O\'Hare et al., [@B50]
                                      PLS[^\*^](#TN1s){ref-type="table-fn"}T[^\*^](#TN1s){ref-type="table-fn"}QAVFR                                             S; T                  This study
  Rv0421c          Rv0421c            GLAEGPLIAGGHS[^\#^](#TN1ss){ref-type="table-fn"}YGGR                                                                      S                     Prisic et al., [@B54]
                                      GLAEGPLIAGGHS[^\*^](#TN1s){ref-type="table-fn"}Y[^\*^](#TN1s){ref-type="table-fn"}GGR                                     S; Y                  This study
  Rv0440           GroEL2             KWGAPTIT[^\$^](#TN1sss){ref-type="table-fn"}NDGVSIAK                                                                      T                     Molle et al., [@B47]
                                      WGAPTIT[^\*^](#TN1s){ref-type="table-fn"}NDGVSIAK                                                                         T                     This study
                                      AVEKVT[^\#^](#TN1ss){ref-type="table-fn"}ETLLK                                                                            T                     Molle et al., [@B48]
                                      VTET[^\*^](#TN1s){ref-type="table-fn"}LLK                                                                                 T                     This study
  Rv0497           Rv0497             RGDSDAITVAELT[^\$^](#TN1sss){ref-type="table-fn"}GEIPIIR                                                                  T                     Prisic et al., [@B54]; This study
                                      T[^\*^](#TN1s){ref-type="table-fn"}GPHPETESSGNR                                                                           T                     This study
  Rv0685           Tuf                PDLNET[^\$^](#TN1sss){ref-type="table-fn"}KAFDQ                                                                           T                     Sajid et al., [@B58]
                                      VLHDKFPDLNET[^\*^](#TN1s){ref-type="table-fn"}K                                                                           T                     This study
  Rv0733           Adk                LGIPQISTGELFR                                                                                                             Not known             Prisic et al., [@B54]
                                      LGIPQIS[^\*^](#TN1s){ref-type="table-fn"}TGELFR                                                                           S                     This study
  Rv0822c          Rv0822c            VHDDADDQQDTEAIAIPAHSLEFLSELPDLR                                                                                           Not Known             Prisic et al., [@B54]
                                      VHDDADDQQDT[^\*^](#TN1s){ref-type="table-fn"}EAIAIPAHSLEFLSELPDLR                                                         T                     This study
  Rv0896           GltA2              ADTDDT[^\$^](#TN1sss){ref-type="table-fn"}ATLR                                                                            T                     Prisic et al., [@B54]; This study
  Rv0931c          PknD               PGLTQT[^\$^](#TN1sss){ref-type="table-fn"}GTAVG                                                                           T                     Durán et al., [@B16]; This study
                                      AASDPGLT[^\*^](#TN1s){ref-type="table-fn"}QT[^\*^](#TN1s){ref-type="table-fn"}GTAVGTYNYMAPER                              T                     This study
                                      WSPGDS[^\*^](#TN1s){ref-type="table-fn"}AT[^\*^](#TN1s){ref-type="table-fn"}VAGPLAADSR                                    S; T                  This study
                                      WSPGDSATVAGPLAADSR                                                                                                        Not known             Prisic et al., [@B54]
                                      WSPGDS[^\*^](#TN1s){ref-type="table-fn"}AT[^\*^](#TN1s){ref-type="table-fn"}VAGPLAADSR                                    S; T                  This study
                                      WSPGDS[^\*^](#TN1s){ref-type="table-fn"}ATVAGPLAADS[^\*^](#TN1s){ref-type="table-fn"}R                                    S                     This study
  Rv1388           MihF               AQEIMTELEIAPT[^\$^](#TN1sss){ref-type="table-fn"}RR                                                                       T                     Prisic et al., [@B54]; This study
  Rv1719           Rv1719             S[^\$^](#TN1sss){ref-type="table-fn"}GGIQVIAR                                                                             S                     Prisic et al., [@B54]This study
  Rv1746           PknF               DDTRVS[^\$^](#TN1sss){ref-type="table-fn"}QPVAV                                                                           S                     Durán et al., [@B16]; This study
  Rv1747           Rv1747             YPTGGQQLWPPSGPQR                                                                                                          T                     Prisic et al., [@B54]
                                      YPT[^\*^](#TN1s){ref-type="table-fn"}GGQQLWPPS[^\*^](#TN1s){ref-type="table-fn"}GPQR                                      S; T                  This study
                                      IPAAPPSGPQPR                                                                                                              Not known             Prisic et al., [@B54]
                                      IPAAPPS[^\*^](#TN1s){ref-type="table-fn"}GPQPR                                                                            S                     This study
  Rv1820           IlvG               STDTAPAQTMHAGR                                                                                                            Not Known             Prisic et al., [@B54]
                                      STDT[^\*^](#TN1s){ref-type="table-fn"}APAQTMHAGR                                                                          T                     This study
  Rv1827           GarA               DQTSDEVTVETTSVFR                                                                                                          Not known             Prisic et al., [@B54]
                                      DQTSDEVT[^\*^](#TN1s){ref-type="table-fn"}VET[^\*^](#TN1s){ref-type="table-fn"}T[^\*^](#TN1s){ref-type="table-fn"}SVFR    T                     This study
                                      VTVETT[^\$^](#TN1sss){ref-type="table-fn"}SVFRA                                                                           T                     Prisic et al., [@B54]; This study
                                      DQTSDEVTVET[^\$^](#TN1sss){ref-type="table-fn"}TSVFR                                                                      T                     Villarino et al., [@B71]; This study
                                      DQT[^\*^](#TN1s){ref-type="table-fn"}SDEVTVET[^\*^](#TN1s){ref-type="table-fn"}TSVFR                                      T                     This study
                                      DQTSDEVT[^\*^](#TN1s){ref-type="table-fn"}VET[^\*^](#TN1s){ref-type="table-fn"}TSVFR                                      T                     This study
                                      DQTSDEVTVET[^\*^](#TN1s){ref-type="table-fn"}T[^\*^](#TN1s){ref-type="table-fn"}SVFR                                      T                     This study
                                      DQTSDEVT[^\*^](#TN1s){ref-type="table-fn"}VET[^\*^](#TN1s){ref-type="table-fn"}T[^\*^](#TN1s){ref-type="table-fn"}SVFR    T                     This study
  Rv2094c          TatA               VDPSAASGQDS[^\*^](#TN1s){ref-type="table-fn"}T[^\*^](#TN1s){ref-type="table-fn"}EARPA                                     S; T                  This study
                                      AEASIETPTPVQSQR                                                                                                           Not known             Prisic et al., [@B54]
                                      AEAS[^\*^](#TN1s){ref-type="table-fn"}IETPTPVQSQR                                                                         S                     This study
                                      AEASIETPT[^\*^](#TN1s){ref-type="table-fn"}PVQSQR                                                                         T                     Prisic et al., [@B54]; This study
                                      VDPSAASGQDSTEARPA                                                                                                         Not known             Chou et al., [@B11]
                                      VDPSAASGQDST[^\*^](#TN1s){ref-type="table-fn"}EARPA                                                                       T                     This study
  Rv2127           AnsP1              ERLGHT[^\$^](#TN1sss){ref-type="table-fn"}GPFPAVANPPVR                                                                    T                     Prisic et al., [@B54]; This study
  Rv2151c          FtsQ               VADDAADEEAVT[^\#^](#TN1ss){ref-type="table-fn"}EPLATESK                                                                   T                     Prisic et al., [@B54]; This study
  Rv2197c          Rv2197c            MAEAEPATRPT[^\#^](#TN1ss){ref-type="table-fn"}GASVR                                                                       T                     Prisic et al., [@B54]; This study
                                      MAEAEPAT[^\#^](#TN1ss){ref-type="table-fn"}RPTGASVR                                                                       T                     Prisic et al., [@B54]
                                      MAEAEPAT[^\*^](#TN1s){ref-type="table-fn"}RPT[^\*^](#TN1s){ref-type="table-fn"}GASVR                                      T                     This study
  Rv2198c          MmpS3              ASGNHLPPVAGGGDKLPSDQTGETDAYSR                                                                                             Not known             Prisic et al., [@B54]
                                      ASGNHLPPVAGGGDKLPSDQT[^\*^](#TN1s){ref-type="table-fn"}GETDAY[^\$^](#TN1sss){ref-type="table-fn"}SR                       T; Y                  Kusebauch et al., [@B33]; This study
  Rv2536           Rv2536             ADDSPTGEMQVAQPEAQTAAVATVER                                                                                                Not known             Prisic et al., [@B54]
                                      AADTDVFSAVR                                                                                                               Not known             Prisic et al., [@B54]
                                      AADT[^\*^](#TN1s){ref-type="table-fn"}DVFS[^\*^](#TN1s){ref-type="table-fn"}AVR                                           T                     This study
  Rv2536           Rv2536             EAPT[^\$^](#TN1sss){ref-type="table-fn"}EVIR                                                                              T                     Prisic et al., [@B54]; This study
                                      ADDSPT[^\*^](#TN1s){ref-type="table-fn"}GEMQVAQPEAQTAAVAT[^\*^](#TN1s){ref-type="table-fn"}VER                            T                     This study
                                      ADDS[^\*^](#TN1s){ref-type="table-fn"}PTGEMQVAQPEAQTAAVATVER                                                              S                     This study
  Rv2606c          SnzP               MDPAGNPATGT[^\$^](#TN1sss){ref-type="table-fn"}AR                                                                         T                     Prisic et al., [@B54]; This study
                                      MDPAGNPAT[^\*^](#TN1s){ref-type="table-fn"}GTAR                                                                           T                     This study
  Rv2694c          Rv2694c            RIPGIDT[^\$^](#TN1sss){ref-type="table-fn"}GR                                                                             T                     Prisic et al., [@B54]; This study
  Rv2696c          Rv2696c            EAAAAQADT[^\#^](#TN1ss){ref-type="table-fn"}QRQAAAGVAR                                                                    T                     Prisic et al., [@B54]
                                      EAAAAQADT[^\*^](#TN1s){ref-type="table-fn"}QR                                                                             T                     This study
  Rv2921           FtsY               IDTSGLPAVGDDATVPR                                                                                                         Not known             Prisic et al., [@B54]
                                      IDTS[^\*^](#TN1s){ref-type="table-fn"}GLPAVGDDATVPR                                                                       S                     This study
                                      IDT[^\*^](#TN1s){ref-type="table-fn"}SGLPAVGDDAT[^\*^](#TN1s){ref-type="table-fn"}VPR                                     T                     This study
                                      IDT[^\*^](#TN1s){ref-type="table-fn"}SGLPAVGDDAT[^\*^](#TN1s){ref-type="table-fn"}VPR                                     T                     This study
  Rv2940c          Mas                ALAQYLADTLAEEQAAAPAAS[^\$^](#TN1sss){ref-type="table-fn"}                                                                 S                     Prisic et al., [@B54]; This study
  Rv2996c          SerA1              SATTVDAEVLAAAPK                                                                                                           Not known             Prisic et al., [@B54]
                                      SAT[^\*^](#TN1s){ref-type="table-fn"}TVDAEVLAAAPK                                                                         T                     This study
                                      S[^\*^](#TN1s){ref-type="table-fn"}ATTVDAEVLAAAPK                                                                         S                     This study
  Rv3181c          Rv3181c            LAALDST[^\#^](#TN1ss){ref-type="table-fn"}DTLER                                                                           T                     Prisic et al., [@B54]
                                      LAALDST[^\*^](#TN1s){ref-type="table-fn"}DT[^\*^](#TN1s){ref-type="table-fn"}LER                                          T                     This study
  Rv3197           Rv3197             S[^\#^](#TN1ss){ref-type="table-fn"}KDEVTAELMEK                                                                           S                     Prisic et al., [@B54]
  Rv3200c          Rv3200c            QSGADTVVVSS[^\$^](#TN1sss){ref-type="table-fn"}ETAGR                                                                      S                     Prisic et al., [@B54]; This study
                                      QSGADTVVVS[^\*^](#TN1s){ref-type="table-fn"}SETAGR                                                                        S                     This study
  Rv3248c          SahH               GVTEETTTGVLR                                                                                                              Not known             Prisic et al., [@B54]
                                      GVTEETT[^\*^](#TN1s){ref-type="table-fn"}T[^\*^](#TN1s){ref-type="table-fn"}GVLR                                          T                     This study
                                      GVTEET[^\*^](#TN1s){ref-type="table-fn"}TTGVLR                                                                            T                     This study
  Rv3604c          Rv3604c            TADTPPDDSGGLHAR                                                                                                           Not known             Prisic et al., [@B54]
                                      TADTPPDDS[^\*^](#TN1s){ref-type="table-fn"}GGLHAR                                                                         S                     This study
                                      DPLTGGQSVADLMAR                                                                                                           Not known             Prisic et al., [@B54]
                                      DPLT[^\$^](#TN1sss){ref-type="table-fn"}GGQSVADLMAR                                                                       T                     Prisic et al., [@B54]; This study
  Rv3801c          FadD32             FDPEDTSEQLVIVGER                                                                                                          Not known             Prisic et al., [@B54]
                                      FDPEDT[^\*^](#TN1s){ref-type="table-fn"}SEQLVIVGER                                                                        T                     This study
  Rv3817           Rv3817             LWQAEDDS[^\*^](#TN1s){ref-type="table-fn"}S[^\*^](#TN1s){ref-type="table-fn"}R                                            S                     This study
                                      RLWQAEDDSSR                                                                                                               Not known             Prisic et al., [@B54]
  Rv3868           EccA1              LAQVLDIDT[^\$^](#TN1sss){ref-type="table-fn"}LDEDRLR                                                                      T                     Prisic et al., [@B54]; This study

Novel phosphorylated amino acid identified in this study.

Phosphorylated residue identified in previous studies.

Phosphorylated residue identified in current and previous studies.

![**Functional classification of phosphorylated proteins**. Percentage phosphorylated proteins per functional category were classified according to Tuberculist. Number of phosphorylated proteins identified in each functional category depicted above the black bars.](fmicb-06-00006-g0002){#F2}

###### 

**Serine/threonine kinases and their phosphorylation sites identified in this study**.

  **STPK**   **Phosphorylated residue (position in protein)**         **Phosphopeptides**                                                                                                   **References**
  ---------- -------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- -----------------------
  PknA       T^8^, S^10^, T^224^, S^299^, T^301^, T^302^              AAPAAIPS[^\*^](#TN2s){ref-type="table-fn"}GT[^\*^](#TN2s){ref-type="table-fn"}T[^\*^](#TN2s){ref-type="table-fn"}AR   This study
                                                                      VGVT[^\*^](#TN2s){ref-type="table-fn"}LS[^\*^](#TN2s){ref-type="table-fn"}GR                                          This study
                                                                      RPFAGDGALT[^\#^](#TN2ss){ref-type="table-fn"}VAMK                                                                     Prisic et al., [@B54]
  PknB       S^169^, T^171^, T^173^, S^305^, T^309^                   AIADSGNS[^\*^](#TN2s){ref-type="table-fn"}VT[^\*^](#TN2s){ref-type="table-fn"}QTAAVIGTAQYLSPEQAR                      This study
                                                                      TSLLSSAAGNLS[^\*^](#TN2s){ref-type="table-fn"}GPRTDPLPR                                                               This study
                                                                      AIADSGNSVT[^\*^](#TN2s){ref-type="table-fn"}QT[^\*^](#TN2s){ref-type="table-fn"}AAVIGTAQYLSPEQAR                      This study
                                                                      TSLLSSAAGNLSGPRT[^\*^](#TN2s){ref-type="table-fn"}DPLPR                                                               This study
  PknD       T^169^, T^171^, S^332^,T^334^,S^343^,S^350^              GGNWPS[^\*^](#TN2s){ref-type="table-fn"}QTGHSPAVPNALQASLGHAVPPAGNK                                                    This study
                                                                      WSPGDS[^\*^](#TN2s){ref-type="table-fn"}AT[^\*^](#TN2s){ref-type="table-fn"}VAGPLAADSR                                This study
                                                                      WSPGDS[^\*^](#TN2s){ref-type="table-fn"}ATVAGPLAADS[^\*^](#TN2s){ref-type="table-fn"}R                                This study
                                                                      AASDPGLT[^\*^](#TN2s){ref-type="table-fn"}QT[^\*^](#TN2s){ref-type="table-fn"}GTAVGTYNYMAPER                          This study
  PknE       S^304^                                                   LPVPSTHPVS[^\*^](#TN2s){ref-type="table-fn"}PGTR                                                                      This study
  PknF       T^289^, S^290^                                           LGGAGDPDDT[^\*^](#TN2s){ref-type="table-fn"}RVS[^\*^](#TN2s){ref-type="table-fn"}QPVAVAAPAK                           This study
  PknG       S^10^, T^14^, T^23^, S^24^, T^26^, S^31^, T^32^, T^55^   PLS[^\*^](#TN2s){ref-type="table-fn"}T[^\*^](#TN2s){ref-type="table-fn"}QAVFR                                         This study
                                                                      S[^\*^](#TN2s){ref-type="table-fn"}GPGT[^\*^](#TN2s){ref-type="table-fn"}QPADAQTATSATVR                               This study
                                                                      SGPGTQPADAQTAT[^\*^](#TN2s){ref-type="table-fn"}S[^\*^](#TN2s){ref-type="table-fn"}ATVRPLSTQAVFR                      This study
                                                                      PDFGDEDNFPHPTLGPDT[^\*^](#TN2s){ref-type="table-fn"}EPQDR                                                             This study
                                                                      SGPGTQPADAQTAT[^\*^](#TN2s){ref-type="table-fn"}SAT[^\*^](#TN2s){ref-type="table-fn"}VR                               This study
  PknH       T^174^                                                   LTQLGT[^\*^](#TN2s){ref-type="table-fn"}AVGTWK                                                                        This study
  PknJ       S^498^                                                   HLADLAS[^\*^](#TN2s){ref-type="table-fn"}IWRR                                                                         This study
  PknL       S^306^, T^309^                                           S[^\*^](#TN2s){ref-type="table-fn"}RIT[^\*^](#TN2s){ref-type="table-fn"}QQGQLGAK                                      This study

Novel phosphorylation sites identified in this study.

Phosphorylated residue identified in previous studies.

We detected 13 Y phosphorylation sites located on 10 proteins in *M. tuberculosis* during early-logarithmic growth. Six of the 13 Y phosphorylation sites (Table [3](#T3){ref-type="table"}) were located on two proteins, FhaA and MmpS3 (Kusebauch et al., [@B33]) and have recently been described in a *M. tuberculosis* H~37~Rv at stationary growth phase. The remaining 7 Y phosphorylated sites were uniquely identified in this study. Amongst these with known annotations were 2 virulence factors (GroS and GroEL2) and Ppa involved in macromolecule biosynthesis.

###### 

**Tyrosine phosphorylation sites identified**.

  **Rv number**   **Protein name**   **Tyrosine phosphopeptides**                                                                                                  **Biological Function**       **References**
  --------------- ------------------ ----------------------------------------------------------------------------------------------------------------------------- ----------------------------- --------------------------------------
  Rv0020c         FhaA               GGQGQGRPDEY[^\*^](#TN3s){ref-type="table-fn"}YDDR                                                                             Signal transduction           This study
                                     GGYPPETGGYPPQPGY[^\*^](#TN3s){ref-type="table-fn"}PRPR                                                                                                      This study
                                     HEEGSY[^\*^](#TN3s){ref-type="table-fn"}VPSGPPGPPEQR                                                                                                        This study
                                     HPDQGDY[^\$^](#TN3ss){ref-type="table-fn"}PEQIGYPDQGGYPEQR                                                                                                  Kusebauch et al., [@B33]; This study
                                     QDYGGGADY[^\$^](#TN3ss){ref-type="table-fn"}TR                                                                                                              Kusebauch et al., [@B33]; This study
                                     VPGY[^\$^](#TN3ss){ref-type="table-fn"}APQGGGYAEPAGR                                                                                                        Kusebauch et al., [@B33]; This study
  Rv0421c         Rv0421c            GLAEGPLIAGGHS[^\*^](#TN3s){ref-type="table-fn"}Y[^\*^](#TN3s){ref-type="table-fn"}GGR                                         Hypothetical                  This study
  Rv0440          GroEL2             QEIENSDSDY[^\$^](#TN3ss){ref-type="table-fn"}DREK                                                                             Protein refolding             Kusebauch et al., [@B33]; This study
  Rv0613c         RecC               IVLAGY[^\*^](#TN3s){ref-type="table-fn"}DEELLER                                                                               Exonuclease V gamma chain     This study
  Rv1513          Rv1513             HQDAFPPANY[^\*^](#TN3s){ref-type="table-fn"}VGAQR                                                                             Hypothetical                  This study
  Rv2198c         MmpS3              ASGNHLPPVAGGGDKLPSDQT[^\*^](#TN3s){ref-type="table-fn"}GETDAY[^\*^](#TN3s){ref-type="table-fn"}SR                             Integral Membrane protein     This study
                                     AYS[^\*^](#TN3s){ref-type="table-fn"}APESEHVTGGPY[^\$^](#TN3ss){ref-type="table-fn"}VPADLR                                                                  Kusebauch et al., [@B33]
                                     AYS[^\*^](#TN3s){ref-type="table-fn"}APESEHVT[^\*^](#TN3s){ref-type="table-fn"}GGPY[^\*^](#TN3s){ref-type="table-fn"}VPADLR                                 This study
  Rv3418c         GroS               Y[^\*^](#TN3s){ref-type="table-fn"}GGTEIK                                                                                     Response to stress            This study
  Rv3628          Ppa                HFFVHY[^\*^](#TN3s){ref-type="table-fn"}K                                                                                     Phosphate metabolic process   This study

^\#^Previously identified pY site.

Novel pY site identified in this study.

pY site identified in current and previous studies.

A large number of proteins involved in intermediary metabolism and respiration processes such as lipid and fatty acid metabolism (KasB, FadD32, AccD4, and MmaA3) were found to be phosphorylated in this study (Supplemental Table [S2](#SM1){ref-type="supplementary-material"}). In addition, several proteins from the ESX-1 type seven secretion system (T7SS) in *M. tuberculosis* including EspR, EccA, CFP10, EspI, EspL, EspB were amongst the identified phosphorylated proteins (Supplemental Table [S1](#SM1){ref-type="supplementary-material"}). We also identified virulence factors such Pks15, AceA5, FadD5, EsxB, KatG, GlpX, Rv2032, and PtbB that were phosphorylated in this hyper-virulent *M. tuberculosis* strain (Supplemental Table [S2](#SM1){ref-type="supplementary-material"}).

Of the 21 phosphorylated proteins involved in information pathways, we identified 6 phosphorylated ribosomal proteins; two phosphorylated small subunit (30S) ribosomal proteins (S3, S19), and four large subunit (50S) ribosomal proteins (L3, L24, L29, L31) with a total of 8 S/T phosphorylation sites. In addition, phosphorylated sites on the ribosomal proteins RpsS and RplX were also identified (Table [4](#T4){ref-type="table"}).

###### 

**List of phosphorylated ribosomal proteins identified in this study and other bacteria**.

  **Protein name**   **Protein name**            **Phosphopeptides**                                             **Phospho-residue**   **References**
  ------------------ --------------------------- --------------------------------------------------------------- --------------------- --------------------------
  *rpsC*             *Streptomyces coelicolor*   Not known                                                       Not known             Mikulík et al., [@B45]
                     *M. tuberculosis*           NPES[^\*^](#TN4s){ref-type="table-fn"}QAQLVAQGVAEQLSNR          S                     This study
                                                 AAGGEEAAPDAAAPVEAQSTES[^\*^](#TN4s){ref-type="table-fn"}        S                     This study
  *rpsS*             *M. tuberculosis*           HVPVFVTES[^\*^](#TN4s){ref-type="table-fn"}MVGHK                S                     This study
  *rplC*             *Streptomyces coelicolor*   Not known                                                       Not known             Mikulík et al., [@B45]
                     *Streptococcus pneumonia*   Not known                                                       Not known             Zhang et al., [@B79]
                     *Halobacterium salinarum*   Not known                                                       Not known             Aivaliotis et al., [@B1]
                     *M. tuberculosis*           IVVEVCSQCHPFYT[^\*^](#TN4s){ref-type="table-fn"}GK              T                     This study
  *rplX*             *M. tuberculosis*           S[^\*^](#TN4s){ref-type="table-fn"}GGIVTQEAPIHVSNVMVVDSDGKPTR   S                     This study
  *rpmC*             *Streptococcus agalatiae*   FQAAAGQLEKT[^\*^](#TN4s){ref-type="table-fn"}AR                 T                     Burnside et al., [@B9]
                     *Streptomyces coelicolor*   RERELGIET[^\*^](#TN4s){ref-type="table-fn"}VESA                 T                     Manteca et al., [@B41]
                     *Listeria monocytogenes*    FQLATGQLENT[^\*^](#TN4s){ref-type="table-fn"}AR                 T                     Misra et al., [@B46]
                                                 DLSTTEIQDQEK                                                    Not known             Misra et al., [@B46]
                     *Lactococcus lactis*        MKLSETK                                                         Not known             Soufi et al., [@B66]
                     *M. tuberculosis*           ELGLATGPDGKES[^\*^](#TN4s){ref-type="table-fn"}                 S                     This study
  *rpmE*             *Klebsiella pneumonia*      S[^\*^](#TN4s){ref-type="table-fn"}TVGHDLNLDVCGK                S                     Lin et al., [@B37]
                     *Halobacterium salinarum*   ASSEFDDRFVTVPLRDVTK                                             Not known             Aivaliotis et al., [@B1]
                     *M. tuberculosis*           T[^\*^](#TN4s){ref-type="table-fn"}GGLVMVR                      T                     This study

Novel pY site identified in this study.

Discussion {#s4}
==========

Here we report 214 phosphorylated proteins extracted during early-logarithmic growth phase from a hyper-virulent clinical Beijing genotype *Mycobacterium tuberculosis* isolate. These proteins can be categorized into different biological functions according to Tuberculist (Lew et al., [@B35]). The impact of phosphorylation on these Hank\'s type Ser/Thr kinases (STPKs), phosphatases and their substrates, and the functional role of phosphorylated residues still remains to be elucidated. However, as in previous studies, the identification of phosphorylated residues clearly suggests functional importance.

Regulatory proteins
-------------------

In recent years, bacterial S/T/Y kinases and phosphatases have been extensively investigated, with indications that they might play a crucial role in pathogenicity. These Hank\'s type kinases have the ability to short-circuit the host defense mechanism since they are mostly involved in key biological processes. We identified phosphopeptides from 9 of the 11 STPKs encoded by the *M. tuberculosis* genome. This included both previously described S/T phosphorylation sites (Boitel et al., [@B7]; Young et al., [@B78]; Durán et al., [@B16]; Villarino et al., [@B71]; Molle et al., [@B47]; O\'Hare et al., [@B50]; Prisic et al., [@B54]; Sajid et al., [@B58]; Chou et al., [@B11]; Kusebauch et al., [@B33]) and novel sites on these STPKs thereby highlighting the complexity of the signal transduction mechanism of this pathogen. Phosphorylated peptides were not detected for PknI and PknK. However MS/MS spectra for these peptides for these proteins were detected with mass spectrometry thereby confirming the presence of these proteins (data not shown).

Of the phosphorylated STPKs, PknA, PknB, and PknG have been shown to be essential for *in vitro* growth (Sassetti et al., [@B60]) and to regulate cell growth and cell division and interfere with host signaling pathways (Fernandez et al., [@B17]). PknE, PknH, PknJ, and PknL have been implicated in the adaptation to the extracellular environment or intracellular survival of *M. tuberculosis* (Sharma et al., [@B63]; Lakshminarayan, [@B34]; Arora et al., [@B3]; Parandhaman et al., [@B52]) which is in agreement with reports that during early growth the bacilli undergo a period of adaptation to their external environment (Stock et al., [@B67]; Soares et al., [@B64]). PknE is involved in the suppression of apoptosis during nitrate stress (Kumar and Narayanan, [@B32]) and intracellular survival and adaptation to hostile environments (Parandhaman et al., [@B52]). In *M. tuberculosis*, PknH controls the expression of a variety of cell wall related enzymes and regulates *in vivo* growth in mice (Zheng et al., [@B80]). PknJ undergoes autophosphorylation and phosphorylates the Thr^168^, Thr^171^, and Thr^173^ residues of Embr (a transcriptional regulator), MmaA4/Hma (a methyltransferase involved in mycolic acid biosynthesis) and PepE (a peptidase located adjacent to the *pknJ* gene in the *M. tuberculosis* genome), respectively (Jang et al., [@B26]). Lastly, PknL is involved in an adaptive response to nutrient starvation. This kinase regulates transcription which allows the bacilli to maintain metabolic activity without sourcing energy from elsewhere (Lakshminarayan, [@B34]). Furthermore, we identified a number of STPK substrates that were phosphorylated in clinical hyper-virulent *M. tuberculosis* strain (list not shown) thereby highlighting the complexity of the phosphorylation regulatory network in *M. tuberculosis*. Even though the role of STPKs in bacterial physiology is not yet fully understood the data presented here could underpin a targeted approach to improving our understanding of STPK-mediated signal transduction mechanisms in *M. tuberculosis*.

Tyrosine phosphorylation
------------------------

The *M. tuberculosis* genome encodes for two putative tyrosine phosphatases (PtpA and PtpB) but is not predicted to encode tyrosine kinases (Cole et al., [@B12]; Bach et al., [@B4]). Most bacterial phosphorylation sites are on serine and threonine; a survey of 11 bacterial phosphoproteomes revealed that S/T phosphorylation accounted for an average of 48 and 40% of phosphorylated sites, respectively, while tyrosine phosphorylation events account for less than 10% of the overall phosphoproteome (Ge and Shan, [@B19]). Tyrosine phosphorylated proteins have been previously shown to play important regulatory roles through their involvement in biological functions such as exopolysaccharide production, DNA metabolism, stress responses (Ge et al., [@B20]; Whitmore and Lamont, [@B73]). Recently, Kusebauch et al. identified tyrosine phosphorylated proteins in *M. tuberculosis* and demonstrated that a number of STPKs can phosphorylate tyrosine in either *cis* or *trans* (Kusebauch et al., [@B33]). This suggests that STPKs have the ability to phosphorylate S/T/Y. In this study we identified 13 tyrosine phosphorylation sites in 8 proteins (Table [3](#T3){ref-type="table"}). An overlap of three proteins (FhaA, MmpS3, and GroES) and 6 tyrosine phosphorylated sites we similar between this and the previous study (Kusebauch et al., [@B33]). Five of the tyrosine phosphorylated proteins (FhaA, GroEL2, MmpS3, GroES, and Ppa) identified in this study are essential for *in vitro* growth (Sassetti et al., [@B60]; Griffin et al., [@B22]) and involved in a variety of functions.

This study confirmed and expanded work by Kusebauch et al., where multiple tyrosine phosphopeptides were identified for FhaA. FhaA is a regulatory protein which has been implicated in cell wall biosynthesis (Fernandez et al., [@B17]) and has a strong association with PknA and PknB (Pallen et al., [@B51]; Roumestand et al., [@B57]). We found that the highly S/T/Y phosphorylated FHA-domain contained 6 tyrosine phosphopeptides of which 4 were previously been identified in H~37~Rv (Kusebauch et al., [@B33]). FhaA is a major substrate of PknB and has been implicated in the formation of a regulatory complex with MviN required for peptidoglycan biosynthesis (Warner and Mizrahi, [@B72]). In our dataset, we found that all three of the proteins (PknB, FhaA, and MviN) in the regulator complex were phosphorylated.

We also confirm the presence of a previously reported Y phosphopeptide of MmpS3 and identified a second phosphopeptide. MmpS3 forms part of the mycobacterial membrane protein small family and is an essential protein for mycobacterial growth and cholesterol metabolism (Griffin et al., [@B23]). The role of phosphorylation of this protein has yet to be determined.

The two proteins GroEL2 and GroES have been identified as potential candidates for antituberculosis treatment (Al-Attiyah et al., [@B2]). We confirmed the presence of the Y phosphopeptide in GroEL2 identified in H~37~Rv (Kusebauch et al., [@B33]). Recently it has been shown that the antigen GroES is sufficient to protect BALB/c mice against challenge infection (Lima et al., [@B36]) and up-regulated in kanamycin and amikacin resistant isolates (Kumar et al., [@B31]). Ppa is an inorganic pyrophosphate and is involved in macromolecule biosynthesis. The *M. tuberculosis* Ppa is highly similar to a well conserved homolog of *Legionella. pneumophila* PPase which is induced in macrophages, although the *M. tuberculosis* PPa promotor is not responsive to any specific intracellular triggers (Triccas and Gicquel, [@B70]).

Virulence factors
-----------------

The identification of virulence factors is crucial in order to improve our understanding of the mechanisms involved in pathogenesis of *M. tuberculosis*. Several of the phosphorylated virulence factors identified in this study were found to be involved in basic metabolic pathways such a lipid and fatty acid metabolism, secretion systems and response and adaptation to environmental changes. The virulence factor KasB and key enzymes (FadD32, AccD4, and MmaA3) in the mycolic acids biosynthesis pathway were phosphorylated in this hyper-virulent *M. tuberculosis* strain. The *kasB* gene is not essential for growth, however, the deletion mutant, Δ*kasB*, resulted in an alteration in growth morphology and loss of acid-fast staining (Bhatt et al., [@B5]). This suggests that modification of this protein could influence the synthesis of mycolic acids and thereby the pathogenicity of the bacilli.

The specialized ESX-1 Type VII secretion system (T7SS), unique to pathogenic mycobacteria is responsible for the secretion of two culture filtrate proteins EsxA and EsxB (ESAT-6 and CFP-10). These secretion systems have been shown to be involved in virulence and are critical for intracellular survival (Bitter and Kuijl, [@B6]) due to their ability to secrete proteins that lack classical signal peptides across the complex cell envelope to host cells during infection (Houben et al., [@B25], p. 5). *M. tuberculosis* have several different ESX regions (ESX-1 to ESX-5) (Daleke et al., [@B14]) with varying gene numbers and size for each of these secretion machinery. In this study we found 6 T7SS proteins to be phosphorylated in the hyper-virulent strain. In a previous study, proteomics of whole cell extracts of this hyper-virulent *M. tuberculosis* strain revealed an under-representation of virulence factors such as ESAT-6 and Esx-like proteins (de Souza et al., [@B15]). The authors showed the abundance of ESAT-6 gene expression was reduced in the hyper-virulent *M. tuberculosis* suggesting that the low levels of this protein might be as a result of its ability to export these proteins more efficiently into the extracellular environment (de Souza et al., [@B15]).

Protein synthesis and interactions
----------------------------------

The impact of phosphorylation on the functionality of ribosomal proteins is not fully understood. Mikulik et al. hypothesized that phosphorylation of ribosomal proteins induces or stabilizes conformational changes during proteins synthesis which could allow modification of subunit association or changes in interactions with proteins and RNAs (Mikulík et al., [@B45]). According to the protein phosphorylation database, phosphopeptides of RpmC have been identified in four different bacteria (Soufi et al., [@B66]; Burnside et al., [@B9]; Manteca et al., [@B41]; Misra et al., [@B46]). The implication of phosphorylation on RpmC has not been investigated. However, in *E.coli*, RpmC, RplW and Trigger factor are located at the exit tunnel in the ribosome, suggesting that phosphorylation may impact on multiple stages of transcription (Kramer et al., [@B30]). In our study we identified phosphopeptides for 7 ribosomal proteins. We also identified unique phosphopeptides on ribosomal proteins RpsS and RplX (Table [3](#T3){ref-type="table"}).

Overlap of phosphorylated proteins with other bacteria
------------------------------------------------------

Twenty-five of phosphorylated proteins identified in our study were also identified in phosphoproteomics studies of other bacteria such as *Klebsiella pneumonia* (Lin et al., [@B37]), *Helicobacter pylori* (Ge et al., [@B20]), *Steptococcus pneumonia* (Sun et al., [@B68]), *Bacillus subtillis* (Macek et al., [@B40]), *Halobacterium salinarum* (Aivaliotis et al., [@B1]), etc. (Table [4](#T4){ref-type="table"}). In our dataset the distribution of S/T/Y seem to be bias toward pT and is in accordance with previously described phosphoproteomes of *M. tuberculosis* (Prisic et al., [@B54]; Kusebauch et al., [@B33]). Manual evaluation of the genome found an over-representation of Threonine relative to Serine (52:48%). This compared to other bacteria such as *Acinetobacter baumannii* (Soares et al., [@B65]), *Bacillus subtilis* (Macek et al., [@B40]), *Escherichia coli* (Macek et al., [@B38]; Soares et al., [@B64]) and *Halobacterium salinarum* (Aivaliotis et al., [@B1]), *Pseudomonas aeruginosa* (Ravichandran et al., [@B55]), and *Streptomyces coelicolor* (Parker et al., [@B53]) which demonstrate a bias toward pS.

Forty-five of the phosphorylated proteins identified in our study were previously described for *M. tuberculosis* H~37~Rv (Boitel et al., [@B7]; Young et al., [@B78]; Molle et al., [@B49], [@B47]; Durán et al., [@B16]; Kang et al., [@B27]; Villarino et al., [@B71]; O\'Hare et al., [@B50]; Thakur et al., [@B69]; Prisic et al., [@B54]; Sajid et al., [@B58]; Gee et al., [@B21]). The reason for not identifying all of the previously identified phosphorylated proteins in the protein phosphorylation database could be ascribed to different genetic backgrounds of the analyzed *M. tuberculosis* strains, culture conditions, sample preparation and different MS-based proteomics approaches used in each of the studies. Our analysis was performed on a hyper-virulent clinical isolate of *M. tuberculosis* and a member of the Beijing genotype which is genetically distinct from the laboratory strain *M. tuberculosis* H~37~Rv analyzed by Prisic et al. and Kusebauch et al. In addition, the Prisic et al. study reported on the combined phosphoproteome from 6 different conditions (5 different culture conditions and 2 different growth phases) (Prisic et al., [@B54]) while Kusebauch et al. reported on the phosphoproteome of late-logarithmic phase cultures (Kusebauch et al., [@B33]), whereas our study analyzed early-logarithmic phase cultures. Even though the overlap between our study of clinical *M. tuberculosis* and that of the previously described laboratory *M. tuberculosis* H~37~Rv is low this work substantially extends our knowledge of the *M. tuberculosis* phosphoproteome. During logarithmic growth phase of bacterial growth the cells are adapting to the environment of the growth media and biological process such as RNA synthesis, DNA replication and synthesis of micro- and macromolecules are up-regulated. It is important to note that in this study the whole cell lysate proteins were enriched for phosphopeptides and we detected a number of phosphorylated proteins involved in these biological processes such as fatty acid- and lipid biosynthetic metabolism; RNA modification and translation; DNA repair, replication and modification. It is believed that environmental conditions, cell density and growth phase influence the expression of virulence factors by a pathogen (McIver et al., [@B43]). This is consistent other bacterial phosphoproteomes, thereby emphasizing that S/T/Y phosphorylation is an important process required for the regulation of numerous cellular processes.

Conclusion {#s5}
==========

Recent developments in the methodology and mass spectrometry technology for phosphoproteomics have highlighted the need to explore the involvement of phosphorylation in disease development and progression. However, the impact of the protein phosphorylation cascade on the physiology of pathogenic bacteria such as *M. tuberculosis* has yet to be fully elucidated. Improved preparative techniques and more sensitive instrumentation are required to fully appreciate the complexity of protein modification. This can only be achieved if concomitant methods are developed to elucidate the impact of phosphorylation on protein function. Although this qualitative study was done in clinical hyper-virulent *M. tuberculosis*, without any follow-up validation studies it still provides a valuable resource for further investigating and understanding the impact of protein phosphorylation regulation in *M. tuberculosis*.
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